聚硫酸盐与心力衰竭风险:与聚硫酸盐的比较研究
Takashin Nakayama1, Hidehiro Kaneko2,3, Yuta Suzuki2,4
1Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Nephrology (Carlton, Vic.)
|September 4, 2025
概括
聚乙烯硫酸盐 (SPS) 的使用与心力衰竭 (HF) 的风险增加有关,特别是在老年人中. 这项研究表明,在高血症治疗中,与SPS诱导的负荷相关的潜在风险.
科学领域:
- 心脏病学
- 肝脏病学
- 药理学
背景情况:
- 聚硫酸盐 (SPS) 是一种常见的高血症治疗方法.
- 有关与SPS相关的负载存在担忧.
- 聚硫酸盐 (CPS) 是一种替代结合剂.
研究的目的:
- 评估SPS开始与心力衰竭之间的关联.
- 将SPS治疗患者与CPS治疗患者的HF风险进行比较.
- 研究SPS诱导的负荷对HF发病率的影响.
主要方法:
- 使用全国性索赔数据库进行的回顾性研究 (2014年4月至2023年8月).
- 包括新处方SPS或CPS的患者.
- 基于倾向分数的治疗权重的逆概率 (IPTW) 的HF发病率比较.
主要成果:
- 分析了3481名患者,478人接受了SPS,3003人接受了CPS.
- 使用SPS与患HF的风险增加有关 (HR 1. 24; 95% CI 1. 00-1. 53).
- 这种关联在78岁以上的个体中更为明显.
结论:
- 实践数据显示,使用SPS会增加患HF的可能性.
- 由SPS引起的负荷可能会导致HF风险.
- 需要进一步研究SPS的安全性,特别是对于老年患者.
更多相关视频
相关概念视频
Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure II: Pathophysiology
33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434


